Topical and systemic drugs: Observational study, treatment decisions are made independently as part of routine clinical care. Recruitment and follow-up will be independent on the type of treatment
Study summary
Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation, clinical features and course are also largely unknown. There are currently no reliable markers that could predict or delineate patient subgroups to support patient management. The aim of this project is to identify clinical and molecular factors that correlate with disease, disease subtypes and progression through in-depth long-term clinical characterization of patients with chronic inflammatory skin diseases and examination of individual biomaterials.
Eligibility
Sex
ALL
Min age
0 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* dermatologist-diagnosed inflammatory skin disease
* informed consent
Exclusion Criteria:
* subject and/or the legal guardians are not able to give written informed consent
* pregnant and breastfeeding women
* concurrent participation in a clinical trial
* use of systemic immunosuppressive therapy or phototherapy during the last 4 weeks or receipt of biologics therapy (e.g. dupilumab, tralokinumab) within the last 3 months
* treatment of the target skin areas with topical corticosteroids, calcineurin inhibitors or emollients 24 hours before sample collection
Primary outcome measure(s)
Physician-assessed global disease activity — Baseline, week 2, week 4, every 3 months up to 2 years Change in Investigator Global Assessment (IGA, 0-5)
Patient-reported global disease activity — Baseline, week 2, week 4, every 3 months up to 2 years Change in Patient Global Assessment (IGA, 0-5)
Trial sites (1)
Facility
City
Region
Status
Department of Dermatology and Allergy, University Hospital Schleswig-Holstein
Kiel
Germany
Recruiting
More University Hospital Schleswig-Holstein trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.